Description

Simple

Clinical

Overview

Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, and Lymphoma, Large B-Cell, Diffuse. It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells.

Pharmacology

Indication

Investigated for use/treatment in lymphoma (non-hodgkin's) and multiple myeloma.

Pharmacodynamic

Information currently not available.

Mechanism of action

Information currently not available.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Dacetuzumab
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Abciximab
The risk or severity of adverse effects can be increased when Abciximab is combined with Dacetuzumab.
Abituzumab
The risk or severity of adverse effects can be increased when Dacetuzumab is combined with Abituzumab.
Abrilumab
The risk or severity of adverse effects can be increased when Dacetuzumab is combined with Abrilumab.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Dacetuzumab.
Adecatumumab
The risk or severity of adverse effects can be increased when Adecatumumab is combined with Dacetuzumab.
Aducanumab
The risk or severity of adverse effects can be increased when Aducanumab is combined with Dacetuzumab.
Afelimomab
The risk or severity of adverse effects can be increased when Afelimomab is combined with Dacetuzumab.
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dacetuzumab.
Alirocumab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Dacetuzumab.
Amatuximab
The risk or severity of adverse effects can be increased when Dacetuzumab is combined with Amatuximab.
AMG 108
The risk or severity of adverse effects can be increased when AMG 108 is combined with Dacetuzumab.
Anetumab ravtansine
The risk or severity of adverse effects can be increased when Dacetuzumab is combined with Anetumab ravtansine.
Anifrolumab
The risk or severity of adverse effects can be increased when Anifrolumab is combined with Dacetuzumab.
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Dacetuzumab.
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Dacetuzumab.
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dacetuzumab.
Apolizumab
The risk or severity of adverse effects can be increased when Apolizumab is combined with Dacetuzumab.
Apomab
The risk or severity of adverse effects can be increased when Dacetuzumab is combined with Apomab.
Ascrinvacumab
The risk or severity of adverse effects can be increased when Ascrinvacumab is combined with Dacetuzumab.
Asfotase alfa
The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Dacetuzumab.
1 References
  1. 1 . Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P, Treon SP, Munshi NC, Anderson KC: Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 2004 Apr 15;64(8):2846-52.PubMed: 15087402